Clinical trials: Antidepressant
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
This study will evaluate the effect of antidepressants on sex hormone levels in women and if the potential changes in sex hormone levels are related to sexual side effects.
- Trial name
- NCT00611975
- Testing
- Fluoxetine, Bupropion
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
- Trial name
- NCT01715805
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 85 sites in United States, Puerto Rico
- Volunteers
- 1,022 people
- Sponsor
- Forest Laboratories
Unipolar Depression, Bipolar Depression
The Antidepressant Efficacy of the Anticholinergic Scopolamine
A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if other routes of administration of scopolamine produce antidepressant effects.
- Trial name
- NCT00369915
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03739203
- Testing
- Cariprazine, Antidepressant Therapy (ADT)
- Where
- 112 sites in United States, Canada and 6 more
- Volunteers
- 752 people
- Sponsor
- AbbVie
Depression, HIV
Trial of Collaborative Depression Care Management for HIV Patients
This project will integrate a depression treatment and brief medication adherence counseling intervention into clinical care at three HIV clinics and will use a randomized controlled trial to assess whether, relative to usual…
- Trial name
- SLAM DUNC (NCT01372605)
- Testing
- Measurement-Based Care collaborative depression management, Enhanced Usual Care
- Where
- 4 sites in United States
- Volunteers
- 304 people
- Sponsor
- Duke University
Depression
The ISLAND Study: InSuLa Assessed Needs for Depression
While there are many effective options for treating a major depressive episode, there are no clinical markers that predict the likelihood of remission with an initial trial of either an antidepressant medication or psychotherapy.
- Trial name
- ISLAND (NCT02137369)
- Testing
- Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Depression
Adherence to Antidepressant Treatment in Subjects With Depression
This study aims to determine whether a combination a first-line antidepressant plus "RT2CK17" in a capsule relative to a first-line antidepressant plus placebo in a capsule results in higher rates of medication adherence in…
- Trial name
- NCT03388164
- Testing
- Escitalopram + RT2CK17
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Chronic Kidney Disease, Depression
Chronic Kidney Disease Antidepressant Sertraline Trial
This is a randomized double-blinded placebo-controlled trial to see if treatment with sertraline as compared with placebo tablets will improve depression symptoms in patients with chronic kidney disease who have not yet started…
- Trial name
- CAST (NCT00946998)
- Testing
- Sertraline
- Where
- 2 sites in United States
- Volunteers
- 201 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Treatment Study of Bipolar Depression
The purpose of this study is to determine whether a single intravenous administration of an N-methyl-D-aspartate antagonist is safe and effective for the acute treatment of bipolar depression.
- Trial name
- NCT00947791
- Testing
- ketamine, midazolam
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Disorder, Major
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of flexibly dosed JNJ-42847922 (20 milligram [mg] or 40 mg) compared to flexibly dosed quetiapine extended-release (XR) (150 mg or 300 mg) as adjunctive therapy to an…
- Trial name
- NCT03321526
- Testing
- JNJ-42847922, Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI)
- Where
- 50 sites in United States
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Post Traumatic Stress Disorder, Major Depressive Disorder
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive Disorder (MDD).
- Trial name
- NCT04697693
- Testing
- Escitalopram, Duloxetine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
In this Phase 4 trial we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD) in depressed outpatient…
- Trial name
- NCT02058693
- Testing
- mixed salts amphetamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rush University Medical Center
Depression
Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.
- Trial name
- NCT02487485
- Testing
- Ketamine, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Major Depressive Disorder
Does Dual Therapy Hasten Antidepressant Response?
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates…
- Trial name
- NCT00519428
- Testing
- escitalopram, bupropion extra long (XL), escitalopram + bupropion
- Where
- 2 sites in United States, Canada
- Volunteers
- 245 people
- Sponsor
- New York State Psychiatric Institute
Social Anxiety Disorder
Geodon for the Treatment of Refractory Social Anxiety Disorder
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment…
- Trial name
- SAD (NCT00215150)
- Testing
- Ziprasidone, Sertraline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Major Depressive Disorder
A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD) using the Montgomery…
- Trial name
- NCT01098240
- Testing
- CP-601,927
- Where
- 58 sites in United States
- Volunteers
- 297 people
- Sponsor
- Pfizer
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
PTSD
Sequenced Treatment Effectiveness for Posttraumatic Stress
Individuals with PTSD are more likely to engage in unhealthy behaviors such as tobacco use, drug use, alcohol misuse, and have high rates of morbidity/mortality.
- Trial name
- STEPS (NCT04597190)
- Testing
- Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Written Exposure Therapy
- Where
- 15 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Washington